These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Heterogeneous induction of an invasive phenotype in prostate cancer cells by coculturing with patient-derived fibroblasts. Ishii K; Nakagawa Y; Matsuda C; Katoh D; Ichishi M; Shirai T; Hirokawa Y; Fujiwara M; Sugimura Y; Watanabe M J Cell Biochem; 2021 Jun; 122(6):679-688. PubMed ID: 33480080 [TBL] [Abstract][Full Text] [Related]
4. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy. Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752 [TBL] [Abstract][Full Text] [Related]
5. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor. Patki M; Huang Y; Ratnam M Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779 [TBL] [Abstract][Full Text] [Related]
6. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer. Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514 [TBL] [Abstract][Full Text] [Related]
7. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Gaur S; Gross ME; Liao CP; Qian B; Shih JC Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539 [TBL] [Abstract][Full Text] [Related]
8. NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers. Guzman J; Weigelt K; Neumann A; Tripal P; Schmid B; Winter Z; Palmisano R; Culig Z; Cronauer MV; Muschler P; Wullich B; Taubert H; Wach S BMC Cancer; 2024 Mar; 24(1):346. PubMed ID: 38500100 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Singh KB; Ji X; Singh SV Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299 [TBL] [Abstract][Full Text] [Related]
10. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
11. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens. Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745 [TBL] [Abstract][Full Text] [Related]
12. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy. Quick J; Santos ND; Cheng MHY; Chander N; Brimacombe CA; Kulkarni J; van der Meel R; Tam YYC; Witzigmann D; Cullis PR J Control Release; 2022 Sep; 349():174-183. PubMed ID: 35780952 [TBL] [Abstract][Full Text] [Related]
13. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253 [TBL] [Abstract][Full Text] [Related]
14. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer. Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197 [TBL] [Abstract][Full Text] [Related]
16. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822 [TBL] [Abstract][Full Text] [Related]
17. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Tummala R; Nadiminty N; Lou W; Evans CP; Gao AC Prostate; 2016 Apr; 76(5):445-55. PubMed ID: 26714839 [TBL] [Abstract][Full Text] [Related]
18. Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer. Sasaki T; Ishii K; Iwamoto Y; Kato M; Miki M; Kanda H; Arima K; Shiraishi T; Sugimura Y Lab Invest; 2016 Mar; 96(3):338-49. PubMed ID: 26641067 [TBL] [Abstract][Full Text] [Related]
19. High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth. Szafran AT; Stephan C; Bolt M; Mancini MG; Marcelli M; Mancini MA Prostate; 2017 Jan; 77(1):82-93. PubMed ID: 27699828 [TBL] [Abstract][Full Text] [Related]
20. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model. Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]